Treatment
PD-1 inhibitor clinical trials
We’re tracking 200 recruiting studies that include PD-1 inhibitor, each written for real people, not researchers, below.
Recruiting studies
- NCT05345002RecruitingPhase 2
ATRA plus PD-1 therapy for IDH-mutant recurrent brain tumors
This trial studies whether adding all-trans retinoic acid (ATRA) to an anti–PD-1 immune therapy can slow recurrent or worsening IDH-mutant glioma. It may help by boosting the immune system’s attack on the tumor.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05039801RecruitingPhase 1
Study drug IACS-6274 tested for advanced solid tumors
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Houston, TexasAges 18 years+ - NCT04165772RecruitingPhase 2
Dostarlimab for locally advanced mismatch-repair deficient solid tumors
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
Hartford, ConnecticutAges 18 years+ - NCT06261125RecruitingPhase 2
SBRT plus immunotherapy and targeted drug for liver cancer
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
Guangzhou, GuangdongAges 18–75 - NCT07238881RecruitingPhase 2
Dalpiciclib plus camrelizumab for liver cancer after immunotherapy
This trial tests two drugs, dalpiciclib and camrelizumab, for people with advanced liver cancer (stage C) whose cancer has grown despite previous immunotherapy. The goal is to see if this combination can shrink or slow the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06501391RecruitingPhase 2
Brain radiation plus chemo-immunotherapy for untreated NSCLC with stable brain metastases
This trial tests whether combining brain radiation with chemotherapy and immunotherapy can help people with advanced lung cancer that has spread to the brain but has not yet been treated. It is for those whose tumors do not have certain gene mutations (EGFR, ALK, ROS1).
ShanghaiAges 18 years+ - NCT05142189RecruitingPhase 1
Testing BNT116 for advanced non-small cell lung cancer
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
Lexington, KentuckyAges 18 years+ - NCT07644897RecruitingPhase 2
Thymosin Alpha 1 Plus Anti-PD-1 for Advanced Melanoma in Older Adults
This trial tests a combination of two drugs—thymosin alpha 1 (an immune-boosting protein) and an anti-PD-1 antibody (a cancer immunotherapy)—in patients 60 and older with advanced melanoma that cannot be surgically removed. The goal is to help the immune system fight the cancer more effectively.
Guangzhou, GuangdongAges 60 years+
Common questions
- Are there clinical trials studying PD-1 inhibitor?
- Yes. Clin2 currently lists 200 recruiting studies that include PD-1 inhibitor, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a PD-1 inhibitor trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is PD-1 inhibitor an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether PD-1 inhibitor or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.